Skip to main content

Advertisement

ADVERTISEMENT

Exclusives

News
10/23/2024
DEBx Medical has initiated a 40-patient pilot RCT to examine the safety/efficacy of chemical debridement and curettage in treatment of venous and mixed etiology leg ulcers with primary outcome of percentage wound reduction at 12 weeks. Not...
DEBx Medical has initiated a 40-patient pilot RCT to examine the safety/efficacy of chemical debridement and curettage in treatment of venous and mixed etiology leg ulcers with primary outcome of percentage wound reduction at 12 weeks. Not...
DEBx Medical has initiated a...
10/23/2024
Wound Care
News
10/23/2024
Tactile Medical announces the launch of the next-generation NIMBL pneumatic compression lymphedema platform in the U.S. for the treatment of upper extremity lymphedema. Nimbl is 68% lighter and 40% smaller than previous-generation devices.
Tactile Medical announces the launch of the next-generation NIMBL pneumatic compression lymphedema platform in the U.S. for the treatment of upper extremity lymphedema. Nimbl is 68% lighter and 40% smaller than previous-generation devices.
Tactile Medical announces the...
10/23/2024
Wound Care
News
10/23/2024
BoStem Technologies announces breakthrough results of BioREtain-processed membranes RE-AC (AmnioWrap2) demonstrating a clear advantage in 12-week DFU healing rates compared to SoC. Results of the study have been published in the recent issue...
BoStem Technologies announces breakthrough results of BioREtain-processed membranes RE-AC (AmnioWrap2) demonstrating a clear advantage in 12-week DFU healing rates compared to SoC. Results of the study have been published in the recent issue...
BoStem Technologies announces...
10/23/2024
Wound Care
News
10/23/2024
Celularity expands its current biomaterial portfolio with the acquisition of Rebound, a full-thickness placental-derived allograft matrix, from Sequence LifeScience. The company expects Rebound sales to contribute revenue in Q424 and fulfill...
Celularity expands its current biomaterial portfolio with the acquisition of Rebound, a full-thickness placental-derived allograft matrix, from Sequence LifeScience. The company expects Rebound sales to contribute revenue in Q424 and fulfill...
Celularity expands its current...
10/23/2024
Wound Care
News
10/23/2024
SNN announced that the recently launched RENASYS EDGE Negative Pressure Wound Therapy System has won the Red Dot Award for Design Concepts 2024 in the Medical Devices and Technology Category. SNN previously received the same award in 2021 for...
SNN announced that the recently launched RENASYS EDGE Negative Pressure Wound Therapy System has won the Red Dot Award for Design Concepts 2024 in the Medical Devices and Technology Category. SNN previously received the same award in 2021 for...
SNN announced that the recently...
10/23/2024
Wound Care
News
10/23/2024
A Convatec-sponsored post-market CT of 80 patients will determine the efficacy and safety of EDX110 (NO) in DFUs and VLUs resulting from venous insufficiency or diabetes with primary outcome of percentage area reduction at 12 weeks. Not yet...
A Convatec-sponsored post-market CT of 80 patients will determine the efficacy and safety of EDX110 (NO) in DFUs and VLUs resulting from venous insufficiency or diabetes with primary outcome of percentage area reduction at 12 weeks. Not yet...
A Convatec-sponsored post-market...
10/23/2024
Wound Care
News
10/23/2024
Results of a retro-matched cohort comparing the effectiveness of human keratin matrix (HKM) and SoC in managing full-thickness pressure ulcers found patients treatment with HKM were 2.8 times more likely to experience full wound closure vs...
Results of a retro-matched cohort comparing the effectiveness of human keratin matrix (HKM) and SoC in managing full-thickness pressure ulcers found patients treatment with HKM were 2.8 times more likely to experience full wound closure vs...
Results of a retro-matched...
10/23/2024
Wound Care
News
10/23/2024
A national pilot survey of 780 patients with hard-to-heal wounds reported that many delay seeking professional assistance (51% more than 3 months), and only 4% see a wound care specialist. The majority (57%) of patients delayed treatment...
A national pilot survey of 780 patients with hard-to-heal wounds reported that many delay seeking professional assistance (51% more than 3 months), and only 4% see a wound care specialist. The majority (57%) of patients delayed treatment...
A national pilot survey of 780...
10/23/2024
Wound Care
News
10/23/2024
A study of 12,488 PI/PU patients reported that 50% of all PUs can heal within 20 weeks with optimal SoC. Although Stage 4 lesions took longer to heal, the majority of PUs (Stage 2 and 3) healed by 14 weeks. This data will be used as a...
A study of 12,488 PI/PU patients reported that 50% of all PUs can heal within 20 weeks with optimal SoC. Although Stage 4 lesions took longer to heal, the majority of PUs (Stage 2 and 3) healed by 14 weeks. This data will be used as a...
A study of 12,488 PI/PU patients...
10/23/2024
Wound Care
News
10/23/2024
A 25-patient CT will evaluate the safety and performance of MicroMatrix Flex in subjects with wounds complicated by tunneling and/or undermining features with primary outcome of percentage of closure at 12 weeks measured manually. Not yet...
A 25-patient CT will evaluate the safety and performance of MicroMatrix Flex in subjects with wounds complicated by tunneling and/or undermining features with primary outcome of percentage of closure at 12 weeks measured manually. Not yet...
A 25-patient CT will evaluate...
10/23/2024
Wound Care

Advertisement

Advertisement

Advertisement